Emmes Partners With ILiAD Biotechnologies to Conduct Phase 3 Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine

ILiAD Biotechnologies, LLC recently announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase 3 studies of its lead pertussis vaccine candidate, BPZE1.

 ILiAD selected Emmes Group for their expertise in vaccine development, agility in managing complex clinical trials, strong local market presence, and their integrated technology capabilities. Emmes Groups’ VaxTrials unit has previously demonstrated proficiency and clinical trial excellence through their successful support of ILiAD’s Phase 2 IB-201P BPZE1 study.

Dr. Keith Rubin, CEO of ILiAD Biotechnologies, said “Selecting Emmes Group for our Phase III BPZE1 trials has been a carefully considered strategic decision to ensure the highest standards of clinical research. VaxTrials’ specialization in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in executing our BPZE1 vaccine clinical development plan.”

“We are honored and pleased that ILiAD has selected Emmes Group as its partner to continue the clinical development of BPZE1. We look forward to working closely with ILiAD’s clinical development team on this promising new vaccine, which could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations,” added Sastry Chilukuri, Chief Executive Officer of Emmes Group.

ILiAD Biotechnologies (http://www.iliadbio.com) is a privately held, clinical-stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis. The company is developing and acquiring key technologies, working with leading scientists to overcome the limitations of current vaccines, investigating the impact of B. pertussis in a range of human disease, and is focused on validating its proprietary vaccines in human clinical trials.

Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital (https://www.newmountaincapital.com). The company is transforming the future of clinical research, bringing the promise of new medical discovery closer within reach for patients. Emmes Group was founded as Emmes more than 47 years ago, becoming one of the primary clinical research providers to the US government before expanding into public-private partnerships and commercial biopharma. Emmes Group has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, rare diseases, and neuroscience. Today, the company is transforming the future of clinical research, by creating the industry’s first native digital and AI-based CRO optimized to deliver programs faster, better, and more efficiently. Where human intelligence meets artificial intelligence. For more information, visit ILiAD Biotechnologies and Emmes Group.